Adaptimmune Therapeutics (ADAP) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

ADAP Adaptimmune Therapeutics

Watchlist

0.623
-0.003-0.51%

Close Dec 10 16:00 ET

0.621
-0.002-0.39%

Post 19:56 ET

159.39MMarket Cap-3729P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

First Patient Treated With Adaptimmune's TECELRA(R) (Afamitresgene Autoleucel)
newsfileDec 2 16:00 ET
Express News | Mizuho Maintains Outperform on Adaptimmune Therapeutics, Lowers Price Target to $1.5
BenzingaNov 27 12:34 ET
Mizuho Securities Maintains Adaptimmune Therapeutics(ADAP.US) With Buy Rating
Moomoo NewsNov 27 01:32 ET · Ratings
Adaptimmune Therapeutics Analyst Ratings
BenzingaNov 19 12:41 ET · Ratings
European Equities Traded in the US as American Depositary Decline Slightly in Tuesday Trading
MT NewswiresNov 19 11:18 ET
H.C. Wainwright Maintains Adaptimmune Therapeutics(ADAP.US) With Buy Rating, Maintains Target Price $3.5
Moomoo NewsNov 19 10:32 ET · Ratings

Comments

Jaguar8

Dec 3 08:05

🔴WATCHLIST Tuesday 12/3. NFA. Don’t open position without momentum. Use charts+indicators+order book. NO FOMO.

Note: This seems to be a long list. The rationale is that I al focused on at least 20% gains and not just after bangers. My trading style is to compound those 10-15-20-30% earnings and roll all profit rather than waiting for runners everyday. If runners appear, then I’ll grab it as well. Each has his own style earning.
$Damon Inc (DMN.US)$ Can be my PM gapper. Low float EV stock. IPO las...

Trytosaveabit

Dec 3 05:03

Update

$Adaptimmune Therapeutics (ADAP.US)$ First Patient Treated With Adaptimmune's TECELRA(R) (Afamitresgene Autoleucel)
newsfile· 2 mins ago
Dosing marks a milestone for first engineered cell therapy approved in the U.S. for a solid tumor cancer, synovial sarcoma

Trytosaveabit

Nov 14 06:14

Not to shabby!

$Adaptimmune Therapeutics (ADAP.US)$ Plus DATA to be presented for IGNYTE-ESO Trial of LETE-CEL in patients with SYNOVIAL SARCOMA! on 11/16/24 Saturday at CTOS annual meeting! ((((. Financial Results for the three and nine months ended September 30, 2024
● Cash / liquidity position: As of September 30, 2024, Adaptimmune had cash and cash equivalents of $116.7 million and Total Liquidity2 of $186.1 million, compared to $144.0 million and $146.9 million respectively, as of December 31...

Stock_Drift

Nov 13 22:09

$Adaptimmune Therapeutics (ADAP.US)$

101674396

Oct 31 16:35

$Adaptimmune Therapeutics (ADAP.US)$ .. green when is the pre-market , will drop once open market!!!

Heat List

Overall

No Data

Investment Theme

CAR-T Therapy

Intraday-0.69%